Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine

Antiviral Therapy

Volumn 11, Issue 6, 2006, Pages 693-699

  Marcelin, Anne Genevieve ^a,b   Flandre, Philippe ^c   Furco, Andre ^b,d   Wirden, Marc ^a,b   Molina, Jean Michel ^c   Calvez, Vincent ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; PLACEBO; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ANTI-HIV AGENTS; CODON; DIDANOSINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33749354990     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
2. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994; 169:722-729.
3. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′- dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994; 38:282-287.
4. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-F15.
5. Costagliola D, Descamps D, Calvez V, et al. Presence of thymidine-associated mutations and response to d4T, abacavir and ddI in the control arm of the Narval ANRS 088 trial. 8th Conference on Retroviruses and Opportunistic Infections. 4-8 February 2001, Chicago, IL, USA. Abstract 450.
6. Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-1744.
7. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131
8. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
9. Sturmer M, Staszewski S, Doerr HW, Larder B, Bloor S, Hertogs K. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob Agents Chemother 2003; 47:54-61.
10. Lu J, Whitcomb J, Kuritzkes DR. Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness. J Acquir Immune Defic Syndr 2005; 40:20-23.
11. Stoeckli TC, MaWhinney S, Uy J, et al. Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother 2002; 46:4000-4003.
12. Molina JM, Marcelin AG, Pavie J, et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis 2005; 191:840-847.
13. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17:2635-2643.
14. HIV-1 genotypic drug resistance interpretation's algorithms. http://www.hivfrenchresistance.org/2005/tab1.html (accessed September 2005)
15. Flandre P, Marcelin AG, Pavie J, et al. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir Ther 2005; 10:479-487.
16. Vora S, Marcelin AG, Gunthard HF, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor- experienced patients. AIDS 2006; 20:35-40.
17. Brun-Vezinet F, Descamps D, Ruffault A, et al. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17:1795-1802.
18. th International HIV Drug Resistance Workshop. 7-11 June 2005, Quebec, Canada. Abstract 96.
19. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448.
20. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-F40.
21. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-1666.
22. th International HIV Drug Resistance Workshop. 7-11 June 2005, Quebec, Canada. Abstract 94.
23. Precious HM, Gunthard HF, Wong JK, et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000; 14:31-36.